Association between real-time shear wave elastography findings and HER-2 expression in breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Shear wave elastography (SWE) shows potential for assessing Human Epidermal growth factor Receptor-2 (HER-2) status in breast cancer. The maximum elastic modulus (Emax) combined with lesion size and calcification demonstrated moderate accuracy in predicting HER-2 positivity.
Area Of Science
- Medical Imaging
- Oncology
- Biophysics
Background
- Human Epidermal growth factor Receptor-2 (HER-2) positive breast cancer exhibits aggressive traits and poorer outcomes.
- Accurate HER-2 status determination is crucial for effective breast cancer treatment planning.
- Real-time shear wave elastography (SWE) is explored as a non-invasive method to assess HER-2 expression.
Purpose Of The Study
- To investigate the correlation between real-time shear wave elastography (SWE) parameters and HER-2 expression levels in breast cancer.
- To evaluate the diagnostic performance of SWE in differentiating HER-2 positive from HER-2 negative breast cancer lesions.
Main Methods
- Retrospective analysis of 67 patients with 70 breast cancer lesions (31 HER-2 negative, 39 HER-2 positive).
- Shear wave elastography (SWE) measurements including mean (Emean), maximum (Emax), and minimum (Emin) elastic modulus.
- Receiver operating characteristic (ROC) curve analysis to assess diagnostic efficacy for HER-2 positivity.
Main Results
- HER-2 positive lesions were more frequently larger than 20 mm.
- A significantly lower Emax value was observed in the HER-2 positive group (P<0.05).
- The combination of Emax, lesion size, and calcification yielded the highest Area Under the Curve (AUC) of 0.800, with 66.7% sensitivity and 83.9% specificity.
Conclusions
- Emax, lesion size, and calcification show a moderate association with HER-2 positivity.
- SWE, particularly Emax, may serve as a valuable non-invasive tool to complement existing methods for assessing HER-2 status in breast cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.